Recent investigations have converged on the convergence of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopamine communication. While GLP stimulators are widely employed for managing type 2 T2DM, their unexpected consequences on motivation circuits, specifically mediated by DA systems, are gaining considerable attention. This